至今,GenScript的服务及产品已被Cell, Nature, Science, PNAS等1300多家生物医药类杂志引用近万次,处于行业领先水平。NIH、哈佛、耶鲁、斯坦福、普林斯顿、杜克大学等约400家全球著名机构使用GenScript的基因合成、多肽服务、抗体服务和蛋白服务等成功地发表科研成果,再次证明GenScript 有能力帮助业内科学家Make research easy.

Differential Inhibition of Nav1.7 and Neuropathic Pain by Hybridoma-Produced and Recombinant Monoclonal Antibodies that Target Nav1.7 : Differential activities of Nav1.7-targeting monoclonal antibodies.

Neurosci Bull. 2018-02; 
BangSangsu,YooJiho,GongXingrui,LiuDi,HanQingjian,LuoXin,ChangWonseok,ChenGang,ImSang-Taek,KimYong Ho,StrongJudith A,ZhangMa-Zhong,ZhangJun-Ming,LeeSeok-Yong,JiRu-
Products/Services Used Details Operation
Molecular Biology Reagents … Materials and Methods. Reagents. The hollow fiber bioreactor was from Fiber Cell Systems Inc. (MD); Dulbecco's modified Eagle's medium (DMEM) was from Gibco or Sigma; penicillin- streptomycin was from Gibco; rSVmab was produced by Genscript Co., according to the … Get A Quote
Bacterial Expression System Get A Quote

摘要

The voltage-gated Na channel subtype Nav1.7 is important for pain and itch in rodents and humans. We previously showed that a Nav1.7-targeting monoclonal antibody (SVmab) reduces Na currents and pain and itch responses in mice. Here, we investigated whether recombinant SVmab (rSVmab) binds to and blocks Nav1.7 similar to SVmab. ELISA tests revealed that SVmab was capable of binding to Nav1.7-expressing HEK293 cells, mouse DRG neurons, human nerve tissue, and the voltage-sensor domain II of Nav1.7. In contrast, rSVmab showed no or weak binding to Nav1.7 in these tests. Patch-clamp recordings showed that SVmab, but not rSVmab, markedly inhibited Na currents in Nav1.7-expressing HEK293 cells. Notably... More

关键词

Animal models,Patch clamping (electrophysiology),Primary afferent neuron,Sodium chan